Dendritic cells in the pathogenesis and treatment of human diseases

A Janus Bifrons?

Nathalie Cools, Annacarmen Petrizzo, Evelien Smits, Franco M. Buonaguro, Maria L. Tornesello, Zwi Berneman, Luigi Buonaguro

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Dendritic cells (DCs) represent the bridging cell compartment between a variety of nonself antigens (i.e., microbial, cancer and vaccine antigens) and adaptive immunity, orchestrating the quality and potency of downstream immune responses. Because of the central role of DCs in the generation and regulation of immunity, the modulation of DC function in order to shape immune responses is gaining momentum. In this respect, recent advances in understanding DC biology, as well as the required molecular signals for induction of T-cell immunity, have spurred many experimental strategies to use DCs for therapeutic immunological approaches for infections and cancer. However, when DCs lose control over such 'protective' responses - by alterations in their number, phenotype and/or function - undesired effects leading to allergy and autoimmune clinical manifestations may occur. Novel therapeutic approaches have been designed and currently evaluated in order to address DCs and silence these immunopathological processes. In this article we present recent concepts of DC biology and some medical implications in view of therapeutic opportunities.

Original languageEnglish
Pages (from-to)1203-1222
Number of pages20
JournalImmunotherapy
Volume3
Issue number10
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Dendritic Cells
Therapeutics
Cell Biology
Immunity
Antigens
Cancer Vaccines
Adaptive Immunity
Hypersensitivity
T-Lymphocytes
Phenotype
Infection
Neoplasms

Keywords

  • autoimmunity
  • cancer
  • cell therapy and immunotherapy
  • dendritic cells
  • HIV

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Dendritic cells in the pathogenesis and treatment of human diseases : A Janus Bifrons? / Cools, Nathalie; Petrizzo, Annacarmen; Smits, Evelien; Buonaguro, Franco M.; Tornesello, Maria L.; Berneman, Zwi; Buonaguro, Luigi.

In: Immunotherapy, Vol. 3, No. 10, 10.2011, p. 1203-1222.

Research output: Contribution to journalArticle

@article{d07051db40ba4600b51b95ceffae092f,
title = "Dendritic cells in the pathogenesis and treatment of human diseases: A Janus Bifrons?",
abstract = "Dendritic cells (DCs) represent the bridging cell compartment between a variety of nonself antigens (i.e., microbial, cancer and vaccine antigens) and adaptive immunity, orchestrating the quality and potency of downstream immune responses. Because of the central role of DCs in the generation and regulation of immunity, the modulation of DC function in order to shape immune responses is gaining momentum. In this respect, recent advances in understanding DC biology, as well as the required molecular signals for induction of T-cell immunity, have spurred many experimental strategies to use DCs for therapeutic immunological approaches for infections and cancer. However, when DCs lose control over such 'protective' responses - by alterations in their number, phenotype and/or function - undesired effects leading to allergy and autoimmune clinical manifestations may occur. Novel therapeutic approaches have been designed and currently evaluated in order to address DCs and silence these immunopathological processes. In this article we present recent concepts of DC biology and some medical implications in view of therapeutic opportunities.",
keywords = "autoimmunity, cancer, cell therapy and immunotherapy, dendritic cells, HIV",
author = "Nathalie Cools and Annacarmen Petrizzo and Evelien Smits and Buonaguro, {Franco M.} and Tornesello, {Maria L.} and Zwi Berneman and Luigi Buonaguro",
year = "2011",
month = "10",
doi = "10.2217/imt.11.110",
language = "English",
volume = "3",
pages = "1203--1222",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "10",

}

TY - JOUR

T1 - Dendritic cells in the pathogenesis and treatment of human diseases

T2 - A Janus Bifrons?

AU - Cools, Nathalie

AU - Petrizzo, Annacarmen

AU - Smits, Evelien

AU - Buonaguro, Franco M.

AU - Tornesello, Maria L.

AU - Berneman, Zwi

AU - Buonaguro, Luigi

PY - 2011/10

Y1 - 2011/10

N2 - Dendritic cells (DCs) represent the bridging cell compartment between a variety of nonself antigens (i.e., microbial, cancer and vaccine antigens) and adaptive immunity, orchestrating the quality and potency of downstream immune responses. Because of the central role of DCs in the generation and regulation of immunity, the modulation of DC function in order to shape immune responses is gaining momentum. In this respect, recent advances in understanding DC biology, as well as the required molecular signals for induction of T-cell immunity, have spurred many experimental strategies to use DCs for therapeutic immunological approaches for infections and cancer. However, when DCs lose control over such 'protective' responses - by alterations in their number, phenotype and/or function - undesired effects leading to allergy and autoimmune clinical manifestations may occur. Novel therapeutic approaches have been designed and currently evaluated in order to address DCs and silence these immunopathological processes. In this article we present recent concepts of DC biology and some medical implications in view of therapeutic opportunities.

AB - Dendritic cells (DCs) represent the bridging cell compartment between a variety of nonself antigens (i.e., microbial, cancer and vaccine antigens) and adaptive immunity, orchestrating the quality and potency of downstream immune responses. Because of the central role of DCs in the generation and regulation of immunity, the modulation of DC function in order to shape immune responses is gaining momentum. In this respect, recent advances in understanding DC biology, as well as the required molecular signals for induction of T-cell immunity, have spurred many experimental strategies to use DCs for therapeutic immunological approaches for infections and cancer. However, when DCs lose control over such 'protective' responses - by alterations in their number, phenotype and/or function - undesired effects leading to allergy and autoimmune clinical manifestations may occur. Novel therapeutic approaches have been designed and currently evaluated in order to address DCs and silence these immunopathological processes. In this article we present recent concepts of DC biology and some medical implications in view of therapeutic opportunities.

KW - autoimmunity

KW - cancer

KW - cell therapy and immunotherapy

KW - dendritic cells

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=80054118073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054118073&partnerID=8YFLogxK

U2 - 10.2217/imt.11.110

DO - 10.2217/imt.11.110

M3 - Article

VL - 3

SP - 1203

EP - 1222

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 10

ER -